Vericiguat - Bayer HealthCare Pharmaceuticals/Merck & Co
Alternative Names: BAY 102; BAY-1021189; MK-1242; VERQUVOLatest Information Update: 03 Jul 2024
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer Bayer HealthCare Pharmaceuticals; Merck & Co
- Class Amines; Carbamates; Fluorobenzenes; Heart failure therapies; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vasodilators
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic heart failure
- Phase II Metabolic syndrome
- No development reported Coronary artery disease
Most Recent Events
- 01 Jul 2024 Bayer plans a phase I trial in Heart failure (In volunteers) in Germany (PO, Suspension) (NCT06474208)
- 20 May 2024 Merck Sharp & Dohme plans a MK-1242-043 phase III trial for Chronic heart failure (In children, In adolescents, In adults, In the elderly) (PO) (NCT06428383)
- 18 Apr 2024 Bayer initiates enrolment in a phase-II trial for Chronic heart failure in Argentina and USA (PO) (NCT06195930)